How to buy Equillium stock | $5.63

Equillium Inc is a biotechnology business based in the US. Equillium shares (EQ) are listed on the NASDAQ and all prices are listed in US Dollars. Equillium employs 31 staff and has a market cap (total outstanding shares value) of 0.00.

Equillium stock price (NASDAQ: EQ)

Use our graph to track the performance of EQ stocks over time.

Equillium shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$5.63
52-week range	$3.47 - $11.33
50-day moving average	$6.16
200-day moving average	$6.08
Wall St. target price	$14.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.31

Buy Equillium shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Equillium stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Equillium price performance over time

Historical closes compared with the close of $5.63 from 2021-10-26

1 week (2021-10-20)	-4.09%
1 month (2021-09-27)	-16.72%
3 months (2021-07-27)	-3.60%
6 months (2021-04-27)	-8.46%

1 year (2020-10-27)	-2.26%
2 years (2019-10-25)	73.23%
3 years (2018-10-26)	14.85
5 years (2016-10-23)	N/A

Equillium financials

Gross profit TTM	$0
Return on assets TTM	-28.65%
Return on equity TTM	-58.17%
Profit margin	0%
Book value	$2.89
Market capitalisation	$172.2 million

TTM: trailing 12 months

Shorting Equillium shares

There are currently 506,990 Equillium shares held short by investors – that's known as Equillium's "short interest". This figure is 21.3% down from 643,970 last month.

There are a few different ways that this level of interest in shorting Equillium shares can be evaluated.

Equillium's "short interest ratio" (SIR)

Equillium's "short interest ratio" (SIR) is the quantity of Equillium shares currently shorted divided by the average quantity of Equillium shares traded daily (recently around 98444.660194175). Equillium's SIR currently stands at 5.15. In other words for every 100,000 Equillium shares traded daily on the market, roughly 5150 shares are currently held short.

However Equillium's short interest can also be evaluated against the total number of Equillium shares, or, against the total number of tradable Equillium shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Equillium's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Equillium shares in existence, roughly 20 shares are currently held short) or 0.0314% of the tradable shares (for every 100,000 tradable Equillium shares, roughly 31 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Equillium.

Find out more about how you can short Equillium stock.

Equillium share dividends

We're not expecting Equillium to pay a dividend over the next 12 months.

Equillium share price volatility

Over the last 12 months, Equillium's shares have ranged in value from as little as $3.47 up to $11.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Equillium's is 1.4962. This would suggest that Equillium's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Equillium overview

Equillium, Inc. , a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc.

Frequently asked questions

What percentage of Equillium is owned by insiders or institutions?
Currently 52.375% of Equillium shares are held by insiders and 29% by institutions. How many people work for Equillium?
Latest data suggests 31 work at Equillium. When does the fiscal year end for Equillium?
Equillium's fiscal year ends in December. Where is Equillium based?
Equillium's address is: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 What is Equillium's ISIN number?
Equillium's international securities identification number is: US29446K1060 What is Equillium's CUSIP number?
Equillium's Committee on Uniform Securities Identification Procedures number is: 29446K106